Hematopoietic stem and progenitor cell mobilization in mice

Methods in Molecular Biology

Volumn 1185, Issue , 2014, Pages 43-64

  Hoggatt, Jonathan ^a   Tate, Tiffany A ^a   Pelus, Louis M ^b,c  

^a Harvard University   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTHER CANCER INSTITUTE   (United States)

Author keywords

Granulocyte colony stimulating factor (G CSF); Hematopoietic stem cell (HSC); Mobilization; Mouse models

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; REAGENT;

ANIMAL CELL; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CELL ASSAY; CELL ISOLATION; CONTROLLED STUDY; FEEDING; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; KINETICS; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPARATION TECHNIQUE; STEM CELL MOBILIZATION; ANIMAL; CYTOLOGY; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; ERYTHROCYTE; FEMALE; MALE; PROCEDURES;

ANIMALS; BLOOD CELL COUNT; DRUG ADMINISTRATION ROUTES; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; KINETICS; LEUKOCYTES, MONONUCLEAR; MALE; MICE;

EID: 84925883374     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1133-2_4     Document Type: Article

References (81)

1. Korbling M, Anderlini P (2001) Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98:2900-2908
2. Weaver CH, Hazelton B, Birch R et al (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969
3. Bender JG, To LB, Williams S et al (1992) Defi ning a therapeutic dose of peripheral blood stem cells. J Hematother 1:329-341
4. Bensinger W, Appelbaum F, Rowley S et al (1995) Factors that infl uence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555
5. Ketterer N, Salles G, Raba M et al (1998) High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 91:3148-3155
6. Passos-Coelho JL, Braine HG, Davis JM et al (1995) Predictive factors for peripheral-blood progenitor-cell collections using a single largevolume leukapheresis after cyclophosphamide and granulocyte-macrophage colony- stimulating factor mobilization. J Clin Oncol 13: 705-714
7. Reiffers J, Faberes C, Boiron JM et al (1994) Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 3:185-191
8. Yoon DH, Sohn BS, Jang G et al (2009) Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non- Hodgkin's lymphoma. Transfusion 49:1890-1900
9. Siena S, Schiavo R, Pedrazzoli P et al (2000) Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 18:1360-1377
10. Stiff PJ, Micallef I, Nademanee AP et al (2011) Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 17:1146-1153
11. DiPersio JF (2010) Can every patient be mobilized? Best Pract Res Clin Haematol 23: 519-523
12. Motabi IH, DiPersio JF (2012) Advances in stem cell mobilization. Blood Rev 26:267-278
13. Giralt S, Stadtmauer EA, Harousseau JL et al (2009) International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23:1904-1912
14. Gertz MA, Kumar SK, Lacy MQ et al (2009) Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 43:619-625
15. Schulman KA, Birch R, Zhen B et al (1999) Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 17:1227
16. To LB, Haylock DN, Simmons PJ et al (1997) The biology and clinical uses of blood stem cells. Blood 89:2233-2258
17. Gordan LN, Sugrue MW, Lynch JW et al (2003) Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 44:815-820
18. Pavone V, Gaudio F, Console G et al (2006) Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 37: 719-724
19. Akhtar S, Weshi AE, Rahal M et al (2008) Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 49: 769-778
20. Pusic I, Jiang SY, Landua S et al (2008) Impact of mobilization and remobilization strategies on achieving suffi cient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14:1045-1056
21. Hosing C, Saliba RM, Ahlawat S et al (2009) Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84:335-337
22. Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502
23. Cavo M, Tosi P, Zamagni E et al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25:2434-2441
24. DiPersio JF, Micallef IN, Stiff PJ et al (2009) Phase III prospective randomized doubleblind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony- stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 27:4767-4773
25. DiPersio JF, Stadtmauer EA, Nademanee A et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720-5726
26. Kymes SM, Pusic I, Lambert DL et al (2012) Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care 18:33-41
27. Rettig MP, Ansstas G, DiPersio JF (2012) Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 26:34-53
28. Roberts AW, Foote S, Alexander WS et al (1997) Genetic infl uences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood 89:2736-2744
29. Watters JW, Kloss EF, Link DC et al (2003) A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol 95:1352-1360
30. Xing Z, Ryan MA, Daria D et al (2006) Increased hematopoietic stem cell mobilization in aged mice. Blood 108:2190-2197
31. Hoggatt J, Pelus LM (2012) Hematopoietic stem cell mobilization with agents other than G-CSF. In: Kolonin MG, Simmons PJ (eds) Stem cell mobilization: methods and protocols. Springer, New York, pp 49-67
32. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659-661
33. Johnson MD, Gad SC (2007) The rat. In: Gad SC (ed) Animal models in toxicology, 2nd edn. CRC Press, Boca Raton, pp 150-173
34. Brown AP, Dinger N, Levine BS (2000) Stress produced by gavage administration in the rat. Contemp Top Lab Anim Sci 39:17-21
35. Dobrakovova M, Jurcovicova J (1984) Corticosterone and prolactin responses to repeated handling and transfer of male rats. Exp Clin Endocrinol 83:21-27
36. Hoggatt AF, Hoggatt J, Honerlaw M et al (2010) A spoonful of sugar helps the medicine go down: a novel technique to improve oral gavage in mice. J Am Assoc Lab Anim Sci 49:329-334
37. King AG, Horowitz D, Dillon SB et al (2001) Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specifi c truncated form of the human CXC chemokine GRObeta. Blood 97:1534-1542
38. Pelus LM, Bian H, King AG et al (2004) Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 103: 110-119
39. Pruijt JF, Verzaal P, Van Os R et al (2002) Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin- 8 in mice. Proc Natl Acad Sci U S A 99: 6228-6233
40. Fukuda S, Bian H, King AG et al (2007) The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 110:860-869
41. Hoggatt J, Mohammad KS, Singh P et al (2013) Differential stem- and progenitor- cell traffi cking by prostaglandin E2. Nature 495:365-369
42. Mendez-Ferrer S, Lucas D, Battista M et al (2008) Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452:442-447
43. Lucas D, Battista M, Shi PA et al (2008) Mobilized hematopoietic stem cell yield depends on species-specifi c circadian timing. Cell Stem Cell 3:364-366
44. Golde WT, Gollobin P, Rodriguez LL (2005) A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim (NY) 34:39-43
45. Hill JM, Syed MA, Arai AE et al (2005) Outcomes and risks of granulocyte colonystimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46: 1643-1648
46. Lindemann A, Rumberger B (1993) Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF). Eur J Cancer 29A:2338-2339
47. Saez B, Ferraro F, Yusuf RZ et al (2012) Hematopoietic stem/progenitor cell retention in the bone marrow depends on tissue specifi c heparan sulfate proteoglycans. Blood 112: Abstract 637
48. Broxmeyer HE, Mejia JA, Hangoc G et al (2007) SDF-1/CXCL12 enhances in vitro replating capacity of murine and human multipotential and macrophage progenitor cells. Stem Cells Dev 16:589-596
49. Pelus LM, Broxmeyer HE, Kurland JI et al (1979) Regulation of macrophage and granulocyte proliferation. Specifi cities of prostaglandin E and lactoferrin. J Exp Med 150: 277-292
50. Lowry PA, Zsebo KM, Deacon DH et al (1991) Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from SCA + Linmurine hematopoietic progenitors. Exp Hematol 19:994-996
51. Bradley TR, Hodgson GS (1979) Detection of primitive macrophage progenitor cells in mouse bone marrow. Blood 54:1446-1450
52. McLeod DL, Shreve MM, Axelrad AA (1976) Induction of megakaryocyte colonies with platelet formation in vitro. Nature 261:492-494
53. Johnson GR, Metcalf D (1977) Pure and mixed erythroid colony formation in vitro stimulated by spleen conditioned medium with no detectable erythropoietin. Proc Natl Acad Sci U S A 74:3879-3882
54. Hara H, Ogawa M (1978) Murine hemopoietic colonies in culture containing normoblasts, macrophages, and megakaryocytes. Am J Hematol 4:23-34
55. Fauser AA, Messner HA (1978) Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood. Blood 52:1243-1248
56. Fauser AA, Messner HA (1979) Identifi cation of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neutrophilic granulocytes and erythroblasts. Blood 53:1023-1027
57. Spangrude GJ, Heimfeld S, Weissman IL (1988) Purifi cation and characterization of mouse hematopoietic stem cells. Science 241:58-62
58. Okada S, Nakauchi H, Nagayoshi K et al (1992) In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood 80:3044-3050
59. Ogawa M, Matsuzaki Y, Nishikawa S et al (1991) Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 174:63-71
60. Ikuta K, Weissman IL (1992) Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad Sci U S A 89: 1502-1506
61. Adolfsson J, Borge OJ, Bryder D et al (2001) Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of selfrenewal capacity. Immunity 15:659-669
62. Yang L, Bryder D, Adolfsson J et al (2005) Identifi cation of Lin(-)Sca1(+)kit(+)CD34(+) Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. Blood 105: 2717-2723
63. Osawa M, Hanada K, Hamada H et al (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273:242-245
64. Weissman IL, Shizuru JA (2008) The origins of the identifi cation and isolation of hematopoietic stem cells, and their capability to induce donorspecifi c transplantation tolerance and treat autoimmune diseases. Blood 112: 3543-3553
65. Chen J, Ellison FM, Keyvanfar K et al (2008) Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol 36: 1236-1243
66. Yilmaz OH, Kiel MJ, Morrison SJ (2006) SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity. Blood 107:924-930
67. Kiel MJ, Yilmaz OH, Iwashita T et al (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121: 1109-1121
68. Ogawa M, Tajima F, Ito T et al (2001) CD34 expression by murine hematopoietic stem cells. Developmental changes and kinetic alterations. Ann N Y Acad Sci 938:139-145
69. Challen GA, Boles N, Lin KK et al (2009) Mouse hematopoietic stem cell identifi cation and analysis. Cytometry A 75:14-24
70. Johnnidis JB, Camargo FD (2008) Isolation and functional characterization of side popu lation stem cells. Methods Mol Biol 430: 183-193
71. Srour EF, Yoder MC (2005) Flow cytometric analysis of hematopoietic development. Methods Mol Med 105:65-80
72. Harrison DE (1980) Competitive repopulation: a new assay for long-term stem cell functional capacity. Blood 55:77-81
73. Harrison DE, Jordan CT, Zhong RK et al (1993) Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations. Exp Hematol 21:206-219
74. Shen FW, Tung JS, Boyse EA (1986) Further defi nition of the Ly-5 system. Immunogenetics 24:146-149
75. Hoggatt J, Singh P, Sampath J, Pelus LM (2009) Prostaglandin E2 enhances hematopoietic stem cell homing, survival and proliferation. Blood 113:5444-5555
76. Hoggatt J, Mohammad KS, Singh P, Pelus LM (2013) Prostaglandin E2 enhances long-term repopulation but does not permanently alter inherent stem cell competitiveness. Blood 122:2997-3000
77. Szilvassy SJ, Lansdorp PM, Humphries RK et al (1989) Isolation in a single step of a highly enriched murine hematopoietic stem cell population with competitive long-term repopulating ability. Blood 74:930-939
78. Szilvassy SJ, Humphries RK, Lansdorp PM et al (1990) Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proc Natl Acad Sci U S A 87:8736-8740
79. Taswell C (1981) Limiting dilution assays for the determination of immunocompetent cell frequencies. I Data analysis. J Immunol 126: 1614-1619
80. Benveniste P, Frelin C, Janmohamed S et al (2010) Intermediate-term hematopoietic stem cells with extended but time-limited reconstitution potential. Cell Stem Cell 6:48-58
81. Ogden DA, Mickliem HS (1976) The fate of serially transplanted bone marrow cell populations from young and old donors. Transplantation 22:287-293